Intercept Pharmaceuticals Total Revenue

The latest total revenue for ICPT is $290M as of September 2023. That compares with $330M in the prior-year period — down 12.7% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Intercept Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, ICPT's total revenue moved from $330M to $290M — a 12.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Intercept Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, ICPT currently prints $290M for total revenue, while the sector average sits near $110B. That is roughly 99.7% below the sector mean. Large gaps often invite a closer look at Intercept Pharmaceuticals's growth, margins, and balance sheet.

A total revenue figure of $290M for ICPT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting ICPT's total revenue ($290M), review year-over-year change from $330M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.